Healthy Profits: Keep an Eye on These 2 Buy-Rated Biotech Stocks in May

NASDAQ: ALKS | Alkermes plc - Ordinary Shares News, Ratings, and Charts

ALKS – The biotech industry should thrive amid breakthrough developments and increasing investments this year. Therefore, fundamentally strong biotech stocks, Alkermes (ALKS) and Nippon Shinyaku (NPPNY) might be ideal buys. Read more…

Despite the economic headwinds, the SPDR S&P Biotech ETF (XBI) has gained 5.1% over the past month, indicating investors’ confidence in the industry. Moreover, increasing technological advancement and regulatory permissiveness in key areas of innovation are expected to boost the biotech industry.

Given the backdrop, I think quality biotech stocks Alkermes plc (ALKS) and Nippon Shinyaku Co., Ltd. (NPPNY), which have maintained stable profit margins, could be worth buying now. These stocks are Buy-rated in our proprietary rating system.

Biotechnology is thriving, thanks to technological advancements, with key market players continuously launching new products to strengthen their position in the industry. Data Bridge Market Research predicts that the biotechnology market to reach $10.13 trillion by 2030, growing at a CAGR of 29%.

Moreover, the pandemic has accelerated the shift towards digitalization, telemedicine, and personalized medicine, all of which are expected to drive growth in the industry.

The market for personalized medicine and companion diagnostics is expected to grow due to the increasing prevalence of rare diseases and advancements in understanding the human genome.

The global personalized medicine market is projected to grow at a CAGR of 10.9% to reach $540.12 billion by 2028.

Amidst the trending debate about whether the US will enter a recession this year, Raj Lala, the president and CEO of Evolve Funds, recently commented that even if it does, biotech companies will “continue to perform well.”

Take a look at the stocks mentioned above:

Alkermes plc (ALKS)

Headquartered in Dublin, Ireland, ALKS is a biopharmaceutical company that researches, develops, and commercializes pharmaceutical products to address the unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally.

Its trailing-12-month asset turnover ratio of 0.57x is 64.5% higher than the 0.35x industry average. Its trailing-12-month gross profit margin of 80.48% is 44.6% higher than the 55.65% industry average.

ALKS’ total revenues for the quarter ended March 31, 2023, came in at $287.60 million, compared to $278.55 million for the same period in the prior year. Non-GAAP net income was $2.42 million for the quarter, while its non-GAAP earnings per share was $0.01.

ALKS’s revenue is expected to rise 15.3% year-over-year to $318.39 million for the fiscal second quarter ending June 2023. The company’s EPS for the same quarter is expected to come in at $0.01. Additionally, the stock has topped consensus EPS and revenue estimates in three of the trailing four quarters, which is impressive.

The stock has gained 22.4% over the past six months to close the last trading session at $28.55.

ALKS’s POWR Ratings reflect its promising outlook. The stock has an overall rating of A, which translates to a Strong Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.

ALKS also has a B grade for Growth, Sentiment, Value, and Quality. It is ranked first out of 383 stocks in the Biotech industry.

To access additional ratings for ALKS’s Stability and Momentum, click here.

Nippon Shinyaku Co., Ltd. (NPPNY)

Headquartered in Kyoto, Japan, NPPNY manufactures and sells pharmaceuticals and foodstuffs in Japan and internationally. The company operates through Pharmaceuticals and Functional Food segments.

Its trailing-12-month gross profit margin of 61.12% is 9.8% higher than the 55.65% industry average. Its trailing-12-month asset turnover ratio of 0.65x is 85.1% higher than the 0.35x industry average.

NPPNY’s revenue increased by 3.4% year-on-year to ¥109.92 billion ($821.42 million) in the fiscal third quarter, which ended March 31, 2023. The company’s operating income came in at ¥27.99 billion ($209.15 million), while profit attributable to owners came in at ¥22.67 billion ($169.44 million).

Analysts expect NPPNY’s revenue to rise 12.6% year-over-year to $271.50 million for the fiscal third quarter ended March 2023. Additionally, the stock has topped consensus revenue estimates in three of the trailing four quarters.

The stock has gained marginally over the past month to close the last trading session at $11.30.

NPPNY’s strong fundamentals are reflected in its POWR Ratings. The stock has an overall rating of B, equating to a Buy in our proprietary rating system.

NPPNY also has a B grade for Value, Stability, and Quality. It is ranked #11 in the same industry.

To access additional ratings for NPPNY’s Growth, Sentiment, and Momentum, click here.

What To Do Next?

Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today’s volatile markets:

3 Stocks to DOUBLE This Year >


ALKS shares were unchanged in premarket trading Monday. Year-to-date, ALKS has gained 9.26%, versus a 9.17% rise in the benchmark S&P 500 index during the same period.


About the Author: Nidhi Agarwal


Nidhi is passionate about the capital market and wealth management, which led her to pursue a career as an investment analyst. She holds a bachelor's degree in finance and marketing and is pursuing the CFA program. Her fundamental approach to analyzing stocks helps investors identify the best investment opportunities. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
ALKSGet RatingGet RatingGet Rating
NPPNYGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


Updated 2024 Stock Market Outlook

The bull market continues to rage on with the S&P 500 (SPY) making new highs. That is the past...the question is what does the future hold? That is why 44 year investment veteran Steve Reitmeister provides this updated 2024 Stock Market Outlook to help you carve a path to outperformance the rest of the year. Read on below for the full story...

3 Energy Stocks Set to Soar Beyond Expectations

Given the geopolitical tensions, increasing global oil demand, and supply adjustments, the energy sector is poised for robust growth. Therefore, investors might consider investing in energy stocks TechnipFMC (FTI), Weatherford International (WFRD), and ChampionX (CHX), which are poised to exceed expectations. Keep reading…

Has Carnival (CCL) Stock Turned Into a Buy After Earnings Release?

Carnival Corporation (CCL) reported record revenue in its most recent quarter but still faces a negative bottom line. The collapse of Francis Scott Key Bridge brings more uncertainty to its financials. Given these events, what stance should one take with CCL stock? Read more to find out…

3 China Stocks Positioned for Long-Term Growth

Despite facing challenges, the Chinese economy has demonstrated resilience, as evidenced by recent robust industrial output and retail sales data. Given this outlook, it might be an opportune time to own three top-notch China stocks, JD.com, Inc. (JD), China Automotive Systems (CAAS), and Youdao, Inc. (DAO). Read on…

What Data Should Investors Focus on Now?

The S&P 500 (SPY) is up nearly 50% from the bear market lows. That is a sign the easy money has been made. The next likely catalyst for stocks will probably be the first Fed rate cut...but maybe that is really the final push before a long overdue sell off? Tune in to discover what investment veteran Steve Reitmeister has to say about the market outlook along with his trading plan and top picks to stay ahead of the pack. Read on below for more...

Read More Stories

More Alkermes plc - Ordinary Shares (ALKS) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All ALKS News